Sugi Predict

Sugi Predict / Compounds / SCHEMBL79367

SCHEMBL79367

SCHEMBL79367

Cc1cc2c(s1)Nc1ccccc1N=C2N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 5/20 0.58
▸ CHRM2 P08172 4/20 0.58
▸ CHRM4 P08173 4/20 0.58
▸ CHRM5 P08912 4/20 0.58
▸ CHRM1 P11229 4/20 0.58
▸ CHRM3 P20309 4/20 0.58
▸ DRD1 P21728 4/20 0.58
▸ ADRA1D P25100 4/20 0.58
▸ HTR2A P28223 4/20 0.58
▸ HTR2C P28335 4/20 0.58
▸ ADRA1A P35348 4/20 0.58
▸ HRH1 P35367 4/20 0.58
▸ ADRA1B P35368 4/20 0.58
▸ HTR2B P41595 4/20 0.58
▸ LMNA P02545 4/20 0.58
▸ ADRA2A P08913 3/20 0.58
▸ ADRA2B P18089 3/20 0.58
▸ ADRA2C P18825 3/20 0.58
▸ KCNH2 Q12809 3/20 0.58
▸ GAA P10253 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30040103 0.99 DRD2 (0.57) DRD2CHRM2CHRM4CHRM5CHRM1
Hydrochloric Acid SCHEMBL937256 0.99 DRD2 (0.57) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL12208493 0.85 DRD2 (0.61) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL12227061 0.82 DRD2 (0.62) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL8490022 0.82 CHRM1 (0.58) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL5143133 0.82 DRD2 (0.58) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL22076574 0.82 DRD2 (0.58) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL5243615 0.82 CHRM2 (0.41) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL5564352 0.82 DRD2 (0.41) DRD2CHRM2CHRM4CHRM5CHRM1
SCHEMBL4847022 0.82 CHRM2 (0.41) DRD2CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115201349-A GC analysis method for content of key reagent propionaldehyde and the like in olanzapine starting material 北京万全德众医药生物技术有限公司 2022-10-18 — — CN claimed
CN-110656347-B Electroreduction preparation method of olanzapine intermediate 浙江大学 2020-10-02 — — CN claimed
CN-110656347-A Electroreduction preparation method of olanzapine intermediate 浙江大学 2020-01-07 — — CN claimed
WO-2014157860-A1 PROCESS FOR THE PREPARATION OF HIGH PURITY OLANZAPINE AND CRYSTALLINE FORM II THEREOF DONG-A ST CO., LTD (KR) 2014-10-02 — — WO claimed
EP-1988092-B1 A process for the preparation of olanzapine ADAMED SP ZOO (PL) 2013-11-27 — — EP claimed
EP-2264016-B1 A process for producing pure form form of 2-Methyl-4-(4-Methyl-1-Piperazinyl)-10h-thieno[2,3-B][1,5] benzodiazepine JUBILANT ORGANOSYS LTD (IN) 2013-05-01 — — EP claimed
US-8044196-B2 Process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine JUBILANT ORGANOSYS LIMITED (IN) 2011-10-25 — — US claimed
EP-1963335-B1 PROCESS FOR THE PREPARATION OF OLANZAPINE EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) 2011-05-04 — — EP claimed
EP-1513846-B1 PROCESS OF PREPARATION OF OLANZAPINE FORM I SANDOZ AG (CH) 2011-03-02 — — EP claimed
US-7863442-B2 Processes for the synthesis of olanzapine APOTEX PHARMACHEM INC. (CA) 2011-01-04 — — US claimed
CN-101061124-A A process for the preparation of n-demethylolanzapine ADAMED SP ZOO (PL) 2007-10-24 — — CN claimed
EP-1814886-A1 A PROCESS FOR THE PREPARATION OF N-DEMETHYLOLANZAPINE Adamed SP. Z O.O. (PL) 2007-08-08 — — EP claimed
EP-1778649-A1 A PROCESS FOR PRODUCING PURE FORM OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-b][1,5]BENZODIAZEPINE Jubilant Organosys Limited (IN) 2007-05-02 — — EP claimed
EP-1749010-A2 SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO 2, 3-B 1,5 BENZODIAZEPINE AND SALTS THEREOF LEK Pharmaceuticals D.D. (SI) 2007-02-07 — — EP claimed
WO-2006053870-A1 A PROCESS FOR THE PREPARATION OF N-DEMETHYLOLANZAPINE ADAMED SP. Z O.O. (PL) 2006-05-26 — — WO claimed
WO-2006006180-A1 A PROCESS FOR PRODUCING PURE FORM OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-b][1,5]BENZODIAZEPINE JUBILANT ORGANOSYS LIMITED (IN) 2006-01-19 — — WO claimed
WO-2005090359-A2 SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2, 3-B][1,5]BENZODIAZEPINE AND SALTS THEREOF LEK PHARMACEUTICALS D.D. (SI) 2005-09-29 — — WO claimed
US-20040067936-A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine REDDY'S LABORATORIES LIMITED (IN) 2004-04-08 — — US claimed
EP-1313742-A1 PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE Dr. Reddy's Laboratories Ltd. (IN) 2003-05-28 — — EP claimed
WO-2002018390-A1 PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE DR. REDDY'S LABORATORIES LTD. (IN) 2002-03-07 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067936-A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine CYP2F1, FIS1, CYP4B1 DRD2 123/4885CHRM2 163/4885CHRM4 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.